hVIVO acquired CHIMagents in July 2021, further strengthening our capabilities in human challenge studies.

hVIVO is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge trials.

We provide end-to-end early clinical development services for our broad and long-standing client base of global biopharma companies.

For more information about our company and services: